Please Wait.....
Report
U.S. Vaccines Market By Technology Type (Inactivated Vaccines, Toxoid Vaccines, Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Others) , By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DTP) , Polio, Hepatitis, Other Indications) By End User (Pediatric, Adults, Travelers) : Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-12-01 I 90 Pages I Allied Market Research
The U.S. vaccines market was valued at $16.4 billion in 2023, and is projected to reach $29.1 billion by 2033, growing at a CAGR of 5.9% from 2024 to 2033.
Vaccine is a biological preparation that provides acquired immunity to a particular infectious disease. It contains antigens, which are weakened or inactivated forms of the pathogen, or pieces of the pathogen such as proteins or sugars. When administered, vaccines stimulate the body's immune system to recognize and fight the targeted pathogen, preparing it for future encounters. This proactive approach helps prevent the onset of diseases that can cause significant morbidity and mortality.
Alarming increase in prevalence of infectious diseases, including seasonal flu, influenza, shingles, and pneumonia, has spurred demand for vaccines to prevent outbreaks and mitigate public health risks. According to the Centers for Disease Control and Prevention, seasonal flu infections in the U.S. lead to an average of 140,000 to 710,000 hospitalizations annually, which drives the demand for annual flu vaccines. In addition, U.S. government initiatives, such as the Vaccines for Children program, which provides vaccines at no cost to eligible children, and adult immunization programs, promote access to vaccines, ensuring higher vaccination rates across various population segments and thus driving the market growth. The continuous growth of the vaccine pipeline, with new vaccines targeting diseases like malaria, Zika, and cancer, helps meet unmet medical needs and addresses emerging infectious diseases, further expanding market opportunities. Moreover, the aging U.S. population is significantly augmenting the demand for vaccines like shingles, pneumococcal, and influenza vaccines, as older individuals are more vulnerable to such infections. According to the National Institute on Aging (NIA) in 2020, the U.S. population aged 65 and older is expected to grow from 54 million in 2019 to 94.7 million by 2060. This demographic shift is expected to drive demand for vaccines targeting older adults, including vaccines for shingles and pneumonia. Furthermore, increased awareness and education about the benefits of vaccination, supported by public health campaigns, drive higher vaccination rates and encourage more individuals to get vaccinated against common preventable diseases. However, high costs associated with vaccine research, development, and manufacturing can limit the availability and affordability of vaccines, especially for emerging diseases or smaller market segments. Moreover, public skepticism about vaccine safety, fueled by misinformation and fear, poses a significant barrier to achieving high vaccination rates. On the contrary, breakthroughs in vaccine technology, such as the development of mRNA vaccines, nanoparticle-based vaccines, and adjuvant formulations, contribute to more effective and rapid vaccine production, which are expected to offer remunerative opportunities for the expansion of the market during the forecast period.
The U.S. vaccines market share is segmented on the basis of technology type, indication, and end user. On the basis of technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. Depending on indication, it is classified into pneumococcal disease; influenza; human papilloma virus; meningococcal disease; rotavirus; varicella; measles, mumps, and rubella; diphtheria, pertussis, and tetanus (DTP); polio; hepatitis; and other indications. By end user, it is segregated into pediatric, adults, and travelers.
Competition Analysis
The major players operating in the U.S. vaccines market include Bavarian Nordic, Merck & Co., Inc., Sanofi, Pfizer, Emergent Biosolutions, CSL, Moderna, Inc., Dynavax Technologies, Novavax, Inc., and GSK Plc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Technology Type
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant and Conjugate Vaccines
- Live Attenuated Vaccines
- Others
By Indication
- Pneumococcal Disease
- Influenza
- Human Papilloma Virus
- Meningococcal Disease
- Rotavirus
- Varicella
- Measles, Mumps, and Rubella
- Diphtheria, Pertussis, and Tetanus (DTP)
- Polio
- Hepatitis
- Other Indications
By End User
- Pediatric
- Adults
- Travelers
- Key Market Players
- Bavarian Nordic
- Merck & Co., Inc.
- Sanofi
- Pfizer
- Emergent Biosolutions
- CSL
- Moderna, Inc.
- Dynavax Technologies
- Novavax, Inc.
- GSK plc.
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: U.S. VACCINES MARKET, BY TECHNOLOGY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Technology Type
4.2. Inactivated Vaccines
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.3. Toxoid Vaccines
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.4. Recombinant And Conjugate Vaccines
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.5. Live Attenuated Vaccines
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 5: U.S. VACCINES MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Pneumococcal Disease
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.3. Influenza
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.4. Human Papilloma Virus
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.5. Meningococcal Disease
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.6. Rotavirus
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.7. Varicella
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.8. Measles, Mumps, And Rubella
5.8.1. Key Market Trends, Growth Factors and Opportunities
5.9. Diphtheria, Pertussis, And Tetanus (DTP)
5.9.1. Key Market Trends, Growth Factors and Opportunities
5.10. Polio
5.10.1. Key Market Trends, Growth Factors and Opportunities
5.11. Hepatitis
5.11.1. Key Market Trends, Growth Factors and Opportunities
5.12. Other Indications
5.12.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 6: U.S. VACCINES MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Pediatric
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.3. Adults
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.4. Travelers
6.4.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning,2023
CHAPTER 8: COMPANY PROFILES
8.1. Bavarian Nordic
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Merck And Co., Inc.
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Sanofi
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Pfizer
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Emergent Biosolutions
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. CSL
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Moderna, Inc.
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Dynavax Technologies
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Novavax, Inc.
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. GSK Plc.
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. U.S. VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. U.S. VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 3. U.S. VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 4. BAVARIAN NORDIC: KEY EXECUTIVES
TABLE 5. BAVARIAN NORDIC: COMPANY SNAPSHOT
TABLE 6. BAVARIAN NORDIC: OPERATING SEGMENTS
TABLE 7. BAVARIAN NORDIC: PRODUCT PORTFOLIO
TABLE 8. BAVARIAN NORDIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 9. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 10. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 11. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 12. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 13. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 14. SANOFI: KEY EXECUTIVES
TABLE 15. SANOFI: COMPANY SNAPSHOT
TABLE 16. SANOFI: OPERATING SEGMENTS
TABLE 17. SANOFI: PRODUCT PORTFOLIO
TABLE 18. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 19. PFIZER: KEY EXECUTIVES
TABLE 20. PFIZER: COMPANY SNAPSHOT
TABLE 21. PFIZER: OPERATING SEGMENTS
TABLE 22. PFIZER: PRODUCT PORTFOLIO
TABLE 23. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 24. EMERGENT BIOSOLUTIONS: KEY EXECUTIVES
TABLE 25. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
TABLE 26. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS
TABLE 27. EMERGENT BIOSOLUTIONS: PRODUCT PORTFOLIO
TABLE 28. EMERGENT BIOSOLUTIONS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 29. CSL: KEY EXECUTIVES
TABLE 30. CSL: COMPANY SNAPSHOT
TABLE 31. CSL: OPERATING SEGMENTS
TABLE 32. CSL: PRODUCT PORTFOLIO
TABLE 33. CSL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 34. MODERNA, INC.: KEY EXECUTIVES
TABLE 35. MODERNA, INC.: COMPANY SNAPSHOT
TABLE 36. MODERNA, INC.: OPERATING SEGMENTS
TABLE 37. MODERNA, INC.: PRODUCT PORTFOLIO
TABLE 38. MODERNA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 39. DYNAVAX TECHNOLOGIES: KEY EXECUTIVES
TABLE 40. DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 41. DYNAVAX TECHNOLOGIES: OPERATING SEGMENTS
TABLE 42. DYNAVAX TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 43. DYNAVAX TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 44. NOVAVAX, INC.: KEY EXECUTIVES
TABLE 45. NOVAVAX, INC.: COMPANY SNAPSHOT
TABLE 46. NOVAVAX, INC.: OPERATING SEGMENTS
TABLE 47. NOVAVAX, INC.: PRODUCT PORTFOLIO
TABLE 48. NOVAVAX, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 49. GSK PLC.: KEY EXECUTIVES
TABLE 50. GSK PLC.: COMPANY SNAPSHOT
TABLE 51. GSK PLC.: OPERATING SEGMENTS
TABLE 52. GSK PLC.: PRODUCT PORTFOLIO
TABLE 53. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. U.S. VACCINES MARKET,2024 - 2033
FIGURE 2. SEGMENTATION OF U.S. VACCINES MARKET,2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN U.S. VACCINES MARKET,2024 - 2033
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: U.S. VACCINES MARKET
FIGURE 10. U.S. VACCINES MARKET , BY TECHNOLOGY TYPE,2024 - 2033 ($BILLION)
FIGURE 11. U.S. VACCINES MARKET , BY INDICATION,2024 - 2033 ($BILLION)
FIGURE 12. U.S. VACCINES MARKET , BY END USER,2024 - 2033 ($BILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: U.S. VACCINES MARKET
FIGURE 19. TOP PLAYER POSITIONING,2023
FIGURE 20. BAVARIAN NORDIC: NET SALES, 2022-2024 ($BILLION)
FIGURE 21. BAVARIAN NORDIC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 22. BAVARIAN NORDIC: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 23. MERCK AND CO., INC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 24. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 25. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 26. SANOFI: NET SALES, 2022-2024 ($BILLION)
FIGURE 27. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 28. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 29. PFIZER: NET SALES, 2022-2024 ($BILLION)
FIGURE 30. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 31. PFIZER: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 32. EMERGENT BIOSOLUTIONS: NET SALES, 2022-2024 ($BILLION)
FIGURE 33. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 35. CSL: NET SALES, 2022-2024 ($BILLION)
FIGURE 36. CSL: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. CSL: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 38. MODERNA, INC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 39. MODERNA, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. MODERNA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 41. DYNAVAX TECHNOLOGIES: NET SALES, 2022-2024 ($BILLION)
FIGURE 42. DYNAVAX TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. DYNAVAX TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 44. NOVAVAX, INC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 45. NOVAVAX, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. NOVAVAX, INC.: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 47. GSK PLC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 48. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. GSK PLC.: REVENUE SHARE, BY REGION, 2024 (%)
LIST OF TABLES
TABLE 1. U.S. VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. U.S. VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 3. U.S. VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 4. BAVARIAN NORDIC: KEY EXECUTIVES
TABLE 5. BAVARIAN NORDIC: COMPANY SNAPSHOT
TABLE 6. BAVARIAN NORDIC: OPERATING SEGMENTS
TABLE 7. BAVARIAN NORDIC: PRODUCT PORTFOLIO
TABLE 8. BAVARIAN NORDIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 9. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 10. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 11. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 12. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 13. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 14. SANOFI: KEY EXECUTIVES
TABLE 15. SANOFI: COMPANY SNAPSHOT
TABLE 16. SANOFI: OPERATING SEGMENTS
TABLE 17. SANOFI: PRODUCT PORTFOLIO
TABLE 18. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 19. PFIZER: KEY EXECUTIVES
TABLE 20. PFIZER: COMPANY SNAPSHOT
TABLE 21. PFIZER: OPERATING SEGMENTS
TABLE 22. PFIZER: PRODUCT PORTFOLIO
TABLE 23. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 24. EMERGENT BIOSOLUTIONS: KEY EXECUTIVES
TABLE 25. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
TABLE 26. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS
TABLE 27. EMERGENT BIOSOLUTIONS: PRODUCT PORTFOLIO
TABLE 28. EMERGENT BIOSOLUTIONS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 29. CSL: KEY EXECUTIVES
TABLE 30. CSL: COMPANY SNAPSHOT
TABLE 31. CSL: OPERATING SEGMENTS
TABLE 32. CSL: PRODUCT PORTFOLIO
TABLE 33. CSL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 34. MODERNA, INC.: KEY EXECUTIVES
TABLE 35. MODERNA, INC.: COMPANY SNAPSHOT
TABLE 36. MODERNA, INC.: OPERATING SEGMENTS
TABLE 37. MODERNA, INC.: PRODUCT PORTFOLIO
TABLE 38. MODERNA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 39. DYNAVAX TECHNOLOGIES: KEY EXECUTIVES
TABLE 40. DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 41. DYNAVAX TECHNOLOGIES: OPERATING SEGMENTS
TABLE 42. DYNAVAX TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 43. DYNAVAX TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 44. NOVAVAX, INC.: KEY EXECUTIVES
TABLE 45. NOVAVAX, INC.: COMPANY SNAPSHOT
TABLE 46. NOVAVAX, INC.: OPERATING SEGMENTS
TABLE 47. NOVAVAX, INC.: PRODUCT PORTFOLIO
TABLE 48. NOVAVAX, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 49. GSK PLC.: KEY EXECUTIVES
TABLE 50. GSK PLC.: COMPANY SNAPSHOT
TABLE 51. GSK PLC.: OPERATING SEGMENTS
TABLE 52. GSK PLC.: PRODUCT PORTFOLIO
TABLE 53. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. U.S. VACCINES MARKET,2024 - 2033
FIGURE 2. SEGMENTATION OF U.S. VACCINES MARKET,2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN U.S. VACCINES MARKET,2024 - 2033
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: U.S. VACCINES MARKET
FIGURE 10. U.S. VACCINES MARKET , BY TECHNOLOGY TYPE,2024 - 2033 ($BILLION)
FIGURE 11. U.S. VACCINES MARKET , BY INDICATION,2024 - 2033 ($BILLION)
FIGURE 12. U.S. VACCINES MARKET , BY END USER,2024 - 2033 ($BILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: U.S. VACCINES MARKET
FIGURE 19. TOP PLAYER POSITIONING,2023
FIGURE 20. BAVARIAN NORDIC: NET SALES, 2022-2024 ($BILLION)
FIGURE 21. BAVARIAN NORDIC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 22. BAVARIAN NORDIC: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 23. MERCK AND CO., INC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 24. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 25. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 26. SANOFI: NET SALES, 2022-2024 ($BILLION)
FIGURE 27. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 28. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 29. PFIZER: NET SALES, 2022-2024 ($BILLION)
FIGURE 30. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 31. PFIZER: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 32. EMERGENT BIOSOLUTIONS: NET SALES, 2022-2024 ($BILLION)
FIGURE 33. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 35. CSL: NET SALES, 2022-2024 ($BILLION)
FIGURE 36. CSL: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. CSL: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 38. MODERNA, INC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 39. MODERNA, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. MODERNA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 41. DYNAVAX TECHNOLOGIES: NET SALES, 2022-2024 ($BILLION)
FIGURE 42. DYNAVAX TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. DYNAVAX TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 44. NOVAVAX, INC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 45. NOVAVAX, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. NOVAVAX, INC.: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 47. GSK PLC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 48. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. GSK PLC.: REVENUE SHARE, BY REGION, 2024 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security